Published · Aurelis Peptides
TB-500 and thymosin beta-4 should not be treated as interchangeable names without checking the sequence. Full-length thymosin beta-4 and a short fragment from it are different molecular specifications. Analytical papers examined a preparation called TB-500 containing an acetylated fragment; that does not establish the identity of every product using the name.
Aurelis lists TB-500 10 mg. The listed amount and the molecular identity answer separate questions. Start with the comparison below, then request the identity records for the particular material offered.
What distinguishes the research names?
| Name | What the sources describe | What to confirm |
|---|---|---|
| Thymosin beta-4 | The full-length peptide, commonly described as 43 amino acids | Complete sequence and molecular form |
| TB-500 in analytical papers | N-acetylated LKKTETQ, a seven-amino-acid fragment | Whether the offered material matches that identity |
| Aurelis TB-500 listing | 10 mg listed content; identity confirmed separately | Selected batch specification and matching records |
A primary cell-biology paper describes thymosin beta-4 as a 43-amino-acid protein. Read the thymosin beta-4 study. This full-length identity is distinct from the shorter fragment examined in the analytical work below.
What did the TB-500 analytical studies identify?
Esposito and colleagues reported the identification and characterisation of an N-terminally acetylated fragment corresponding to residues 17–23 of thymosin beta-4 in a formulation called TB-500. The letter sequence is LKKTETQ; “acetylated” identifies a chemical modification at its beginning. Read Esposito et al., 2012.
Ho and colleagues developed an LC-MS method to detect N-acetylated LKKTETQ and its metabolites in equine urine and plasma. That study concerns analytical identification. Read Ho et al., 2012. Neither reference is a laboratory report for an Aurelis batch.
Use the actual test material when reading a paper
Before connecting a study to a catalogue enquiry, check its methods for the peptide sequence, molecular form and source of the test material. A headline using a related name may omit details that matter to the comparison.
Keep the research question separate from the identity question. A study involving full-length thymosin beta-4 cannot establish that a short fragment is the same material. Our BPC-157 vs TB-500 comparison explores the broader recovery-research background; this guide focuses on the naming and specification distinction.
Read the 10 mg listing correctly
The Aurelis entry lists 10 mg as content. It does not state the amino-acid sequence, an amount delivered by a device or a liquid concentration. A matching total mass cannot resolve a different molecular identity.
Ask for the accepted identity and the basis of the stated amount. The content vs concentration guide explains why mass and volume need separate fields. Our quality-documentation guide distinguishes identity, purity and content records so one result does not stand in for another.
Do not resolve a blend abbreviation by assumption
Wolverine lists BPC 10 mg + TB 10 mg. GLOW lists GHK 50 mg + BPC 10 mg + TB 10 mg. These are the source-sheet abbreviations. The letters TB do not by themselves establish a complete molecular specification.
The GLOW vs Wolverine comparison preserves those listed amounts and explains which identities to request. Keep KLOW and Ipamorelin + CJC no DAC specifications on request; a related individual profile does not supply their missing formulation details.
Prepare a precise vial or kit enquiry
Include TB-500 10 mg, requested quantity, preferred vial or pen-style kit format and destination in the USA, Canada or Australia. Ask for the offered sequence and molecular form, matching batch references and confirmation of current presentation and local availability.
Contact Aurelis Peptides or email sales@aurelispeptides.com. A clear identity request helps connect the catalogue name, the analytical records and the material being discussed.